LIAS and neoplasm: When comparing individual tumor sizes (change in tumor area) between day 10 and 23 post-injection, we observed a transient reduction in tumor size in the majority (6/7; 86%) of a-TEA-LS + aPD-1 treated mice as compared to only 2/15 (13%), 4/15 (27%), and 1/6 (17%) of IgG, a-TEA-LS, and a-PD-1-treated control cohorts, respectively (Figure 1C).